Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life science sectors.
Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 142 life science companies, leading to 64 IPOs and 40 mergers and acquisitions.
Clarus is an experienced team of healthcare investors with deep scientific and clinical development expertise. Since inception in 2005, we have been passionate about generating attractive returns by investing in innovative ideas.
Clarus manages $1.7B across three funds and invests through multiple platforms including risk-sharing partnerships, pre-commercial royalties, and traditional venture investments in private and public companies.
We employ a hands-on philosophy and adhere to our investment principles that are founded on our core competencies of scientific and clinical expertise, the knowledge of the regulatory process, and our ability to adapt to an ever changing investment landscape. We strive to generate outstanding returns for our investors and thrive on discovering and developing products that improve people’s lives.
Founded in 1996, Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets.
Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors).
The company’s portfolio includes royalty interests in over 40 approved products including AbbVie’s Humira, AbbVie and J&J’s Imbruvica, Biogen’s Tecfidera, Vertex’s Kalydeco and Orkambi, J&J’s Remicade, Merck’s Januvia, Gilead’s Atripla and Truvada, Pfizer’s Lyrica, and Astellas and Pfizer’s Xtandi. Royalty Pharma is also a leading investor in pre-approval royalties, having committed over $850 million to direct R&D funding in exchange for royalties, and having invested over $4 billion in royalties on pre-approval products since 2011.